 Skin reactions and fever were the most common IARs attributed to alemtuzumab infusions.
Introduction
Infusion-associated reactions (IARs) occur in >90% patients with multiple sclerosis (MS) treated with alemtuzumab, despite all patients receive premedication consisting of 1 g/day IV methylprednisolone immediately before alemtuzumab administration on the first 3 out of 5 days of treatment. (1, 2) Furthermore, most physicians use concomitant treatment with antipyretic and antihistamine.
The aim of this study was to study the frequency of IARs at 2 sites using 5 days of steroids (1g/day of IV methylprednisolone), but otherwise distinct protocols.
Methods
This was retrospective chart review of consecutive patients with relapsing remitting MS who were treated with alemtuzumab from June 2015 till February 2017 at Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia and Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia. All patients received alemtuzumab in outpatient clinic and all adverse events (AE) were recorded on the paper chart and entered in the electronic hospital records. Temperature, blood pressure and heart rate were measured every hour during the infusion, with additional measurements taken if the patient reported new symptoms. Other IARs were spontaneously reported/observed during the infusion visit. AE occurring after the infusion were reported by the patient the next morning and entered in the patient's chart.
IAR were defined as any adverse event beginning during or within 24 hours after an alemtuzumab infusion. Adverse events associated with steroid use (flushing, insomnia, taste changes, elevated blood pressure) were not considered as IARs.
The Croatian cohort received alemtuzumab in an outpatient neurological department, and Slovenian cohort received alemtuzumab in an inpatient neurological department.
Along with his, the need for admitting the patient in the inpatient service was recorded for the Total number of IARs, timing and frequency of IARs in the two cohorts is provided in Table   2 . Skin reactions and fever were the most common IARs attributed to alemtuzumab infusions and they were most frequent on Day 5 and Day 1, respectively ( Figure 1 ). There was a significant difference between groups in the frequency of fever (Table 2 ).
In the Croatian cohort, in 3 patients IARs resulted in hospitalization, in all 3 cases due to worsening of preexisting neurological deficits associated with fever (in one patient paraparesis and in 2 patients cognitive dysfunction). In the Slovenian cohort in one patient the 5 cycle was administered with a 3 days delay due to rash.
Two out of 9 treatments naïve, and 19 out of 29 patients who previously received immunomodulatory treatment had IARs (χ 2 =5.208, p=0.022).
Discussion
With the modification od the premedication given in which we extended methylprednisolone through days 4 and 5, 17 patients (44.7%) did not experience IARs. As well, we have observed a biphasic occurrence of IARs, fever being the most common on the 1 st day, and rash being the most common on the 5 th day of therapy.
Prevention of alemtuzumab associated IARs is of great importance, as some of IARs (especially fever and skin reactions) may lead to treatment discontinuation. In the CARE-MS I and II studies, in 45 patients, the first treatment course was suspended/interrupted, and of these, only 24 patients went on to eventually complete their first and second treatment courses. (3) The most frequently observed IARs in our cohort were skin reactions, occurring in 13 (34.2%) patients, exclusively on days 3 through 5, and peaking on day 5, which is different comparing to 66.1% of patients with skin reactions in the CARE-MS I and II studies (Table   3) . ( has to be noted that this observation may be related to the infusion site, significantly more of the patients in Croatian cohort had had previous disease modifying treatments.
This study has several limitations, first of all retrospective data collection and relatively small number of patients. However, there is clear lack of postmarketing studies on IARs management in patients with MS receiving alemtuzumab.
In conclusion, modified premedication scheme consisting of 1g/day of IV methylprednisolone throughout all 5 days of alemtuzumab treatment may reduce overall IARs. Intravenous administration of antipyretics may work better than oral administration. 
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